ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

Rhea-AI Summary

ALX Oncology Holdings Inc. (Nasdaq: ALXO) has announced an investor conference call and webcast scheduled for July 31, 2024, at 4:30 PM EDT. The purpose of this event is to share topline data results from the Phase 2 ASPEN-06 clinical trial of evorpacept, their investigational therapy for advanced HER2-positive gastric cancer. Evorpacept is designed to block the CD47 immune checkpoint pathway.

Investors and interested parties can access the live conference call by dialing (800) 715-9871 (U.S./Canada) or +44.800.260.6466 (international) with Conference ID 9637001. A live and archived webcast of the call, along with a slide presentation, will be available on the company's website in the News & Events section.

Positive

• ALX Oncology is ready to present topline data from a Phase 2 clinical trial
• The trial focuses on evorpacept for advanced HER2-positive gastric cancer, a significant market
• The company is providing multiple access options for investors to join the call and webcast

Negative

• None.

• Conference Call and Webcast Today at 4:30 PM EDT
  
  

SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, announced that the Company will host an investor conference call and webcast today at 4:30 PM EDT to share topline data results from the Phase 2 ASPEN-06 clinical trial evaluating evorpacept for the treatment of advanced HER2-positive gastric cancer.

To access the live conference call, please dial (800) 715-9871 (U.S./Canada) or +44.800.260.6466 (internationally), Conference ID 9637001. To access the live and archived webcast of the conference call, please visit the News & Events section (see “Events") of the Company’s website at www.alxoncology.com, where a slide presentation will be referenced during the event.

FAQ

What is the purpose of ALX Oncology's investor call on July 31, 2024?

ALX Oncology is hosting an investor call to share topline data results from the Phase 2 ASPEN-06 clinical trial of evorpacept for the treatment of advanced HER2-positive gastric cancer.

What is evorpacept and what is it being developed for by ALXO?

Evorpacept is a therapy being developed by ALX Oncology to block the CD47 immune checkpoint pathway. It is currently being evaluated for the treatment of advanced HER2-positive gastric cancer.

How can investors access ALX Oncology's conference call on July 31, 2024?

Investors can access the live conference call by dialing (800) 715-9871 (U.S./Canada) or +44.800.260.6466 (internationally) with Conference ID 9637001. A live and archived webcast will also be available on the company's website.

What phase is the ASPEN-06 clinical trial for ALXO's evorpacept?

The ASPEN-06 clinical trial for evorpacept is a Phase 2 trial, as mentioned in the press release.